28-Sept-2026 08:54:53
MOREPENLABExpansion
MOREPEN LABORATORIES : FIRST U.S. ANDA SUBMISSION FOR SITAGLIPTIN TABLETS USP
• First U.S. ANDA submitted for Sitagliptin Tablets USP in three strengths • Strengthens formulation, bioequivalence and regulatory dossier capabilities • Supports specialized CDMO opportunities across regulated markets
Morepen Laboratories Ltd
Open attachment